AR107282A1 - TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) - Google Patents

TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)

Info

Publication number
AR107282A1
AR107282A1 ARP170100004A ARP170100004A AR107282A1 AR 107282 A1 AR107282 A1 AR 107282A1 AR P170100004 A ARP170100004 A AR P170100004A AR P170100004 A ARP170100004 A AR P170100004A AR 107282 A1 AR107282 A1 AR 107282A1
Authority
AR
Argentina
Prior art keywords
receiver
glucagon
glp
gip
peptide
Prior art date
Application number
ARP170100004A
Other languages
Spanish (es)
Inventor
Se Chang Kwon
Sung Youb Jung
Chang Ki Lim
Young Jin Park
Jong Suk Lee
Euh Lim Oh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR107282A1 publication Critical patent/AR107282A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere a un agonista triple que tiene actividades para todos los receptores de glucagón, GLP-1, y GIP y usos de los mismos. Asimismo se refiere a una composición para la prevención o el tratamiento del síndrome metabólico que comprende dichos péptidos.The present application refers to a triple agonist that has activities for all glucagon, GLP-1, and GIP receptors and uses thereof. It also refers to a composition for the prevention or treatment of the metabolic syndrome comprising said peptides.

ARP170100004A 2015-12-31 2017-01-02 TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) AR107282A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150191082 2015-12-31

Publications (1)

Publication Number Publication Date
AR107282A1 true AR107282A1 (en) 2018-04-18

Family

ID=62104015

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170100003A AR107281A1 (en) 2015-12-31 2017-01-02 PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP
ARP170100004A AR107282A1 (en) 2015-12-31 2017-01-02 TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170100003A AR107281A1 (en) 2015-12-31 2017-01-02 PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP

Country Status (3)

Country Link
AR (2) AR107281A1 (en)
MA (4) MA42891B2 (en)
MY (1) MY199261A (en)

Also Published As

Publication number Publication date
AR107281A1 (en) 2018-04-18
MA51955B1 (en) 2022-04-29
MA42891A1 (en) 2019-04-30
MY199261A (en) 2023-10-23
MA53533A1 (en) 2022-08-31
MA42891B2 (en) 2021-11-30
MA42889A1 (en) 2018-11-30
MA51955A1 (en) 2021-10-29
MA42889B2 (en) 2020-11-30

Similar Documents

Publication Publication Date Title
CL2022000557A1 (en) Glucagon/glp-1/gip receptor triple agonist (divisional 2 application 202002034)
DOP2018000297A (en) DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME
CL2019001465A1 (en) New compounds as trigonal peptide agonists of glp1 / glucagon / gip receptors.
CL2017001760A1 (en) Co-agonist compounds of gip and glp-1
CR20170129A (en) USE OF A DUAL GLP-1 / GLUCAGON RECEPTOR AGONIST OF LONG-TERM ACTION FOR THE TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE
PE20180449A1 (en) DERIVATIVE OF GLUCAGON AND A COMPOSITION THAT INCLUDES A CONJUGATE OF PROLONGED ACTION OF THE SAME
AR099977A1 (en) DOUBLE PEPTIDE AGONISTS OF THE RECIPIENTS OF THE SIMILAR PEPTIDE TO GLUCAGON 1 (GLP-1) AND OF THE GLUCAGON RECEIVER (GCG), DERIVED FROM EXENDINA-4
CL2014003421A1 (en) Glucagon analogs exhibiting agonist activity at the glusose-dependent insulinotropic peptide receptor (gip): pharmaceutical composition; and method to reduce weight gain or induce weight loss, particularly for the treatment of obesity.
AR102712A1 (en) INSULIN RECEPTOR PARTIAL AGONISTS
EP3463429A4 (en) Insulin receptor partial agonists and glp-1 analogues
UY36779A (en) NEW DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
CL2017001483A1 (en) Fixed ratio formulation of insulin glargine / lixisenatide
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
PH12017501205A1 (en) Glucagon derivatives
AR107282A1 (en) TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)
CR20190161A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
AR102978A1 (en) FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA

Legal Events

Date Code Title Description
FB Suspension of granting procedure